ANEXOS

Tabla 1. Criterios de Búsqueda en Cochrane DAtaBASE

#1	"COVID-19" OR (COVID) OR (Coronavirus) OR (SARS-CoV-2) OR (Coronaviruses) OR (Deltacoronavirus) OR (Deltacoronaviruses) OR "Munia coronavirus HKU13" OR (Coronavirus HKU15) OR (Coronavirus, Rabbit) OR (Rabbit Coronavirus) OR (Coronaviruses, Rabbit) OR (Rabbit Coronaviruses) OR "Bulbul coronavirus HKU11" OR "Thrush coronavirus HKU12	161
#2	(Hydroxychloroquine) OR (Oxychlorochin) OR (Oxychloroquine) OR (Hydroxychlorochin) OR (Plaquenil) OR (Hydroxychloroquine Sulfate) OR "Hydroxychloroquine Sulfate (1:1) Salt" OR (Hidroxicloroquina) OR (Hydroxychloroquine) OR (Hydroxychloroquinum) OR (Oxichlorochine) OR (Oxichloroquine) OR Chlorochin OR Cloroquina OR Cloroquine OR Chloroquine OR (Antimalarials) OR (Antimalarial Agents) OR (Agents, Antimalarial) OR (Antimalarial Drugs) OR (Drugs, Antimalarial) OR (Anti-Malarials) OR (Anti Malarials) OR "(N4-(7-Chloro-4-quinolinyl)-N1,N1-diethyl1,4-pentanediamine)" OR Hydroquin OR Axemal OR Dolquine OR Quensyl OR Quinoric OR Plaquenil OR chloraquin OR chloraquine OR chloroquine OR cloroquin OR chlorokin OR chlorokine OR chlorquin OR chlorquine OR kloroquin OR kloroquine	3993
#3	#1 AND #2	8

Tabla 2 Criterios de Búsqueda en PubMEd

#2	,"Search (""Hydroxychloroquine""[Mesh] OR (Hydroxychloroquine) OR (Oxychlorochin) OR (Oxychloroquine) OR (Hydroxychlorochin) OR (Plaquenil) OR (Hydroxychloroquine Sulfate) OR ""Hydroxychloroquine Sulfate (1:1) Salt"" OR (Hidroxicloroquina) OR (Hydroxychloroquine) OR (Hydroxychloroquinum) OR (Oxichlorochine) OR (Oxichloroquine) OR ""Chloroquine""[Mesh] OR Chlorochin OR Cloroquina OR Cloroquine OR Chloroquine OR ""Antimalarials""[Mesh] OR (Antimalarials) OR (Antimalarial Agents) OR (Agents, Antimalarial) OR (Antimalarial Drugs) OR (Drugs, Antimalarial) OR (Anti-Malarials) OR (Anti Malarials) OR â€œ(N4-(7-Chloro-4-quinolinyl)- N1,N1-diethyl-1,4pentanediamine)â€ OR Hydroquin OR Axemal OR Dolquine OR Quensyl OR Quinoric)"	95714
#1	,"Search ""Coronavirus""[Mesh] OR ""COVID-19"" OR (COVID) OR (Coronavirus) OR (SARS-CoV-2) OR (Coronaviruses) OR (Deltacoronavirus) OR (Deltacoronaviruses) OR ""Munia coronavirus HKU13"" OR (Coronavirus HKU15) OR (Coronavirus, Rabbit) OR (Rabbit Coronavirus) OR (Coronaviruses, Rabbit) OR (Rabbit Coronaviruses) OR ""Bulbul coronavirus HKU11"" OR ""Thrush coronavirus HKU12"")"	20371
#3	"Search ((((""Hydroxychloroquine""[Mesh] OR (Hydroxychloroquine) OR (Oxychlorochin) OR (Oxychloroquine) OR (Hydroxychlorochin) OR (Plaquenil) OR (Hydroxychloroquine Sulfate) OR ""Hydroxychloroquine Sulfate (1:1) Salt"" OR (Hidroxicloroquina) OR (Hydroxychloroquine) OR (Hydroxychloroquinum) OR (Oxichlorochine) OR (Oxichloroquine) OR ""Chloroquine""[Mesh] OR Chlorochin OR Cloroquina OR Cloroquine OR Chloroquine OR ""Antimalarials""[Mesh] OR (Antimalarials) OR (Antimalarial Agents) OR (Agents, Antimalarial) OR (Antimalarial Drugs) OR (Drugs, Antimalarial) OR (Anti-Malarials) OR (Anti Malarials) OR â€œ(N4-(7-Chloro-4-quinolinyl)- N1,N1-diethyl-1,4pentanediamine)â€ OR Hydroquin OR Axemal OR Dolquine OR Quensyl OR Quinoric))) AND (""Coronavirus""[Mesh] OR ""COVID-19"" OR (COVID) OR (Coronavirus) OR (SARS-CoV-2) OR (Coronaviruses) OR (Deltacoronavirus) OR (Deltacoronaviruses) OR ""Munia coronavirus HKU13"" OR (Coronavirus HKU15) OR (Coronavirus, Rabbit) OR (Rabbit Coronavirus) OR (Coronaviruses, Rabbit) OR (Rabbit Coronaviruses) OR ""Bulbul coronavirus HKU11"" OR ""Thrush coronavirus HKU12""))"	144

Tabla 3 Resultados de búsqueda en cochrane database

1. Efficacy and Safety of Hydroxychloroquine for Treatment of Pneumonia Caused by 2019-nCoV (HC-nCoV) NCT04261517 https://clinicaltrials.gov/show/NCT04261517, 2020 | added to CENTRAL: 29 February 2020 | 2020 Issue 02
2. Post-exposure Prophylaxis for SARS-Coronavirus-2 NCT04308668 https://clinicaltrials.gov/show/NCT04308668, 2020 | added to CENTRAL: 31 March 2020 | 2020 Issue 03 EN SANITARIOS Y SUS CONTACTOS
3. Various Combination of Protease Inhibitors, Oseltamivir, Favipiravir, and Chloroquin for Treatment of COVID19 : a Randomized Control Trial NCT04303299 https://clinicaltrials.gov/show/NCT04303299, 2020 | added to CENTRAL: 31 March 2020 | 2020 Issue 03 EN ASOCIACIÓN CON FÁRMACOS QUE NO SON AZITROMICINA
4. The Clinical Study of Carrimycin on Treatment Patients With COVID-19 NCT04286503 https://clinicaltrials.gov/show/NCT04286503, 2020 | added to CENTRAL: 31 March 2020 | 2020 Issue 03EXCLUIDO NO CLOROQUINA
5. Treatment of Mild Cases and Chemoprophylaxis of Contacts as Prevention of the COVID-19 Epidemic NCT04304053 https://clinicaltrials.gov/show/NCT04304053, 2020 | added to CENTRAL: 31 March 2020 | 2020 Issue 03 EN POBLACIÓN GENERAL EN SÍNTOMAS LEVES Y PROFILAXIS POSTEXPOSICIÓN
6. Chloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting NCT04303507 https://clinicaltrials.gov/show/NCT04303507, 2020 | added to CENTRAL: 31 March 2020 | 2020 Issue 03 PROFILAXIS POSTEXPOSICIÓN DURANTE 3 MESES.
7. Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19) NCT04307693 https://clinicaltrials.gov/show/NCT04307693, 2020 | added to CENTRAL: 31 March 2020 | 2020 Issue 03
8. Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19) NCT043076931 https://clinicaltrials.gov/show/NCT04307693, 2020 | added to CENTRAL: 31 March 2020 | 2020 Issue 03 DUPLICADO

Tabla 4: EC con Hidroxicloroquina en ensayos clínicos

Active Substance	Hydroxychloroquine	Hydroxychloroquine Sulfate (Plaquenil®)	Hydroxychloroquine + Azithromycin	Hydroxychloroquine (Plaquenil®)
Sponsor	National Institute of Respiratory Diseases, Mexico; Sanofi	University Hospital, Akershus, Norway	Hospital Israelita Albert Einstein, São Paulo, Brazil	University of Minnesota, USA
Trial identifier	NCT04315896	NCT04316377	NCT04321278	NCT04308668
Study desing	Randomised, parallell assigned, double- blinded, placebo-controlled study	Pragmatic randomised parallell assigned open-label, placebo- controlled study	Randomised, parallell assigned, open- label study	Randomised, parallell assigned, quadruple-blinded, placebo-controlled study
Status trial	Not yet recruiting	Not yet recruiting	recruiting	recruiting
Duration/End of study	7 months/ Estimated October 31, 2020	12 months/ Estimated April 1, 2021	5 months/ Estimated August 30, 2020	1 month/ Estimated April 21, 2020

Tabla 5 Resultados de la búsqueda en pubmed

SYSTEMATIC REVIEW

1. Shah S, Das S, Jain A, Misra DP, Negi VS. A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in Coronavirus Disease-19 (COVID-19). Int J Rheum Dis. 2020 Apr 13. doi: 10.1111/1756-185X.13842. [Epub ahead of print] PubMed PMID: 32281213.

2. Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care. 2020 Mar 10. pii: S0883-9441(20)30390-7. doi:10.1016/j.jcrc.2020.03.005. [Epub ahead of print] PubMed PMID: 32173110.

ESTUDIOS QUE LO ASOCIAN CON AZITROMICINA

1. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Sevestre J, Mailhe M, Doudier B, Aubry C, Amrane S, Seng P, Hocquart M, Eldin C, Finance J, Vieira VE, Dupont HT, Honoré S, Stein A, Million M, Colson P, La Scola B, Veit V, Jacquier A, Deharo JC, Drancourt M, Fournier PE, Rolain JM, Brouqui P, Raoult D. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study. Travel Med Infect Dis. 2020 Apr 11:101663. doi: 10.1016/j.tmaid.2020.101663. [Epub ahead of print] PubMed PMID: 32289548.

2. Garcia-Cremades M, Solans BP, Hughes E, Ernest JP, Wallender E, Aweeka F,Luetkemeyer A, Savic RM. Optimizing hydroxychloroquine dosing for patients with COVID-19: An integrative modeling approach for effective drug repurposing. Clin Pharmacol Ther. 2020 Apr 14. doi: 10.1002/cpt.1856. [Epub ahead of print] PubMed PMID: 32285930
3. Boyarsky BJ, Chiang TP, Werbel WA, Durand CM, Avery RK, Getsin SN, Jackson KR, Kernodle AB, Van Pilsum Rasmussen SE, Massie AB, Segev DL, Garonzik-Wang JM. Early Impact of COVID-19 on Transplant Center Practices and Policies in the United States. Am J Transplant. 2020 Apr 13. doi: 10.1111/ajt.15915. [Epub ahead of print] PubMed PMID: 32282982
4. Juurlink DN. Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection. CMAJ. 2020 Apr 8. pii: cmaj.200528. doi: 10.1503/cmaj.200528. [Epub ahead of print] PubMed PMID: 32269021.
5. Ohe M, Shida H, Jodo S, Kusunoki Y, Seki M, Furuya K, Goudarzi H. Macrolide treatment for COVID-19: Will this be the way forward? Biosci Trends. 2020 Apr 5. doi: 10.5582/bst.2020.03058. [Epub ahead of print] PubMed PMID: 32249257.
6. Sargiacomo C, Sotgia F, Lisanti MP. COVID-19 and chronological aging: senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection? Aging (Albany NY). 2020 Mar 30. doi: 10.18632/aging.103001. [Epub ahead of print] PubMed PMID: 32229706.
7. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, Doudier B, Courjon J, Giordanengo V, Vieira VE, Dupont HT, Honoré S, Colson P, Chabrière E, La Scola B, Rolain JM, Brouqui P, Raoult D. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020 Mar 20:105949. doi: 10.1016/j.ijantimicag.2020.105949. [Epub ahead of print] PubMed PMID: 32205204; PubMed Central PMCID: PMC7102549.

Tabla 6 Informes encontrados en Agencias de Evaluación:

AIHTA Policy Letter No.: 002; 2020 Viena: HTA Austria - Austrian Institute for Health Technology Assessment GmbH.

Tabla 7: La cloroquina en el registro de ensayos clínicos EUDRA-CT

Active Substance	Chloroquine Phosphate	Chloroquine Phosphate	Chloroquine Phosphate	Chloroquine Phosphate
Sponsor	HwaMei Hospital, University of Chinese Academy of Sciences, Zhejiang, China	HwaMei Hospital, University of Chinese Academy of Sciences, Zhejiang, China	Zhongnan Hospital of Wuhan University, Wuhan, China	The First Hospital of Jilin University, Jilin, China
Trial identifier	ChiCTR2000029939	ChiCTR2000029935	ChiCTR2000029988	ChiCTR2000029975
Study desing	Randomised, parallell assigned, single-blinded study	Single arm, open-label, case series study	Randomised, parallell assigned, open- label study	Single-arm, open-label study
Status trial	Recruiting	Recruiting	Recruiting	Not yet recruiting
Duration/End of study	12 months/ Estimated February 6, 2021	12 months/ Estimated February 6, 2021	3 months/ Estimated May 31, 2020	3 months/ Estimated May 31, 2020
Study details	Pts: n = 100 Location: China Intervention: Chloroquine Phosphate (not specified) Control: Standard of care Duration of observation: up to 30 days Primary outcome: Length of hospital stay.	Pts: n = 100 Location: China Intervention: Chloroquine Phosphate (not specified) Control: none Duration of observation: up to 30 days Primary outcome: Length of hospital stay.	Pts: n = 80 Location: China Intervention: Chloroquine Phosphate (not specified) Control: no treatment Duration of observation: not given Primary outcome: Time to clinical recovery	Pts: n = 10 Location: China Intervention: Chloroquine (150 mg dissolved in 5 ml of normal saline, q12h, inhaled by atomization for one week) Control: none Duration of observation: up to 30 days Primary outcome: - Viral negative-transforming time - 30-day cause-specific mortality - Co-infections - Time from severe and critical patients to clinical improvement

. Continuación de la tabla.

Active Substance	Chloroquin Phosphate vs. Hydroxychloroquine Sulfate	Chloroquin Phosphate vs. Hydroxychloroquine Sulfate	Chloroquin Phosphate vs. Hydroxychloroquine Sulfate
Sponsor	Zhongshan Hospital Affiliated to Xiamen University, China	Zhongshan Hospital Affiliated to Xiamen University, China	Peking University Third Hospital, China
Trial identifier	ChiCTR2000030054	ChiCTR2000029992	ChiCTR2000029899
Study desing	Randomised, parallell assigned, open-label, placebo-controlled study	Randomised, parallell assigned, open-label, placebo-controlled study	Randomised, parallell assigned, open-label study
Status trial	Not yet recruiting	Not yet recruiting	Recruiting
Duration/End of study	3 months/ Estimated May 21, 2020	3 months/ Estimated May 20, 2020	2 months/ Estimated April 30, 2020
Study details	Pts: n = 100 Location: China Intervention: - Group 1: Hydroxychloroquine Sulfate (0.2 g bid x14 days/day) - Group 2: Chloroquine Phosphate (first dose 1 g x2 days, third day 0.5 g x12 days) Control: Placebo oral tablet Duration of observation: up to 28 days Primary outcome: Clinical recovery time	Pts: n = 100 Location: China Intervention: - Group 1: Chloroquine Phosphate (first dose 1 g x2 days, third day 0.5 g x12 days) - Group 2: Hydroxychloroquine Sulfate (0.2 g bid x14 days/day) Control: Placebo oral tablet Duration of observation: up to 28 days Primary outcome: Clinical recovery time	Pts: n = 100 Location: China Intervention: - Group 1: Hydroxychloroquine Sulfate (Day1: first dose: 6 tablets (0.1 g/tablet), second dose: 6 tablets (0.1 g/tablet) after 6h; Day2~5: 2 tablets (0.1 g/table), BID) - Group 2: Chloroquine Phosphate (Day 1-3: 500 mg BID; Day 4- 5: 250 mg BID) Control: none Duration of observation: up to 28 days Primary outcome: Time to Clinical Improvement

Study details	Pts: = 500 Location: Mexico Intervention: Hydroxychloroquine (400 mg/day for 10 days) Control: Placebo oral tablet Duration of observation: up to 120 days Primary outcome: Incidence of all-cause mortality	Pts: n = 202 Location: Norway Intervention: Hydroxychloroquine sulfate (400 mg) Control: Placebo oral tablet Duration of observation: up to 90 days Primary outcome: Rate of decline in SARS-CoV-2 viral load assessed by real time polymerase chain reaction in nasopharyngeal samples	Pts: n = 440 Location: Brazil Intervention: Hydroxychloroquine (400 mg 2x/day, 12/12h for 10 days) + Azithromycin (500 mg 1x/day for 10 days) Control: Hydroxychloroquine (400 mg 2x/day, 12/12h for 10 days) D uration of observation: up to 29 days Primary outome: Evaluation of the clinical status of patients on the 15th day after randomisation defined by the ordinal scale of 7 points (score ranges from 1 to 7, with 7 being the worst score)	Pts: n = 3,000 Location: USA Intervention: Hydroxychloroquine (200 mg tablet; 800 mg orally once, followed in 6 to 8 hours by 600 mg, then 600 mg once a day for 4 consecutive days) Control: Placebo oral tablet Duration of observation: up to 14 days Primary outcome: - Number of participants at 14 days post enrollment with active COVID-19 disease - Ordinal Scale of COVID-19 Disease Severity at 14 days among those who are symptomatic at trial entry: 1) no COVID-19 illness; 2) COVID-19 illness with no hospitalization; 3) COVID-19 illness with hospitalization or death

Continuación de la tabla.

Active Substance	Hydroxychloroquine vs. Remdesivir vs. Lopinavir/Ritonavir vs. Lopinavir/Ritonavir + Interferon Beta-1A	Hydroxychloroquine (Plaquenil®)	Hydroxychloroquine (Quensyl®)	Hydroxychloroquine (Plaquenil®)
Sponsor	Institut National de la Santé Et de la Recherche Médicale, France	Oslo University Hospital, Norway	Universitätsklinikum Tübingen, Germany	Fondation Méditerranée Infection - IHU , Méditerranée Infection, France
Trial identifier	NCT04315948 (Part of global WHO SOLIDARTY trial)	EudraCT: 2020-000982-18 (Part of global WHO SOLIDARTY trial)	EudraCT: 2020-001224-33	EudraCT 2020-000890-25
Study desing	Multicenter, randomised, parallell assigned, open-label study	Multicenter, randomised, parallell assigned, open-label study	Randomised, parallell assigned, double- blinded, placebo-controlled study	Single-arm, not blinded study
Status trial	Recruiting	Ongoing	Ongoing	Ongoing
Duration/End of study	36 months/ Estimated March 2023	12 months/ not specified	18 months/ A interim analysis will be done when 40% of events have accrued. In case the interim analysis shows a HR > 1.93 (nominal p < 0.0018), efficacy is shown and the trial may be stopped. Final analysis upon completion of the trial and final database lock	12 months /not specified
Study details	Pts: n = 3,100 Location: France Intervention: - Group 1: Remdesivir (200 mg i.v. Day 1, followed by 100 mg once-daily i.v. for duration of hospitalization up to 10 days) - Group 2: Lopinavir/ritonavir (400 mglopinavir/100 mg ritonavir every 12 h for 14 days tablet form. Patients who are unable to take medications by mouth, 400 mg lopinavir/100 mg ritonavir 5-ml suspension every 12 h for 14 days via nasogastric tube) - Group 3: Lopinavir/ritonavir + Interferon ß-1a 400 mg lopinavir/100 mg	Pts: n = 443 Location: Norway Intervention: Hydroxychloroquine (not specified) Control: Standard of care Duration of observation: not given Primary outcome: In-hospital mortality	Pts: n=220 Location: Germany Intervention: Hydroxychloroquine (not specified) Control: Placebo oral tablet Duration of observation: not given Primary outcome: Viral clearance defined as time to sustained SARS-CoV-2-specific RNA copy number ≤100, measured by real time reverse-transcription polymerase chain reaction in throat swabs	Pts: n = 25 Location: France Intervention: Hydroxychloroquine (not specified) Control: none Duration of observation: at timepoints day 1, day 4, day 7 and day 14 Primary outcome: Results of SARS-COV2 virus detection, not further specified

	ritonavir every 12 h for 14 days in tablet form. Patients who are unable to take medications by mouth 400 mg lopinavir/100 mg ritonavir 5-ml suspension every 12 h for 14 days nasogastric tube. Interferon ß-1a subcutaneously at the dose of 44 µg for a total of 3 doses in 6 days (day 1, day 3, day 6)) - Group 4: Hydroxychloroquine Sulfate (400 mg twice day 1, followed by 400 mg once daily for 9 days. Through nasogastric tube: 600 mg twice day 1, followed by a maintenance dose of 400 mg) Control: Standard of care Duration of observation: 15 days Primary outcome: Percentage of subjects reporting each severity rating on a 7-point ordinal scale: 1) Not hospitalized, no limitations on activities 2) Not hospitalized, limitation on activities; 3) Hospitalized, not requiring supplemental oxygen; 4) Hospitalized, requiring supplemental oxygen; 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 7) Hospitalized, on invasive mechanical ventilation or ECMO; 8) Death			

Continuación de la tabla.

Active Substance	Hydroxychloroquine Sulfate vs. Chloroquin Phosphate	Hydroxychloroquine (Plaquenil®)	Chloroquin Phosphate vs. Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate vs. Chloroquin Phosphate
Sponsor	Zhongshan Hospital Affiliated to Xiamen University, China	Renmin Hospital of Wuhan University, China	Zhongshan Hospital Affiliated to Xiamen University, China	Peking University Third Hospital, China
Trial identifier	ChiCTR2000030054	ChiCTR2000029559	ChiCTR2000029992	ChiCTR2000029898
Study desing	Randomised, parallell assigned, open- label, placebo-controlled study	Singlecentered, randomised, parallell assigned, double-blinded, placebo- controlled study	Randomised, parallell assigned, open- label, placebo-controlled study	Randomised, parallell assigned, open- label study
Status trial	Not yet recruiting	Recruiting	Not yet recruiting	Recruiting
Duration/End of study	3 months/ Estimated May 21, 2020	1 month/ Estimated February 29, 2020	3 months/ Estimated May 20, 2020	2 months/ Estimated April 30, 2020
Study details	Pts: n = 100 Location: China Intervention: - Group 1: Hydroxychloroquine Sulfate (0.2 g bid x14 days/day) - Group 2: Chloroquine Phosphate (first dose 1 g x2 days, third day 0.5 g x12 days) Control: Placebo oral tablet Duration of observation: up to 28 days Primary outcome: - Clinical recovery time	Pts: n = 300 Location: China Intervention: - Group 1: Hydroxychloroquine (0.1 oral 2/day) - Group 2: Hydroxychloroquine (0.2 oral 2/day) Control: Placebo oral tablet Duration of observation: not given Primary outcome: - T cell recovery time - Time when the nucleic acid of the novel coronavirus turns negative	Pts: n = 100 Location: China Intervention: - Group 1: Chloroquine Phosphate (first dose 1 g x2 days, third day 0.5 g x12 days) - Group 2: Hydroxychloroquine Sulfate (0.2 g bid x14 days/day) Control: Placebo oral tablet Duration of observation: up to 28 days Primary outcome: - Clinical recovery time	Pts: n = 100 Location: China Intervention: - Group 1: Hydroxychloroquine Sulfate (Day1: first dose: 6 tablets (0.1 g/tablet), second dose: 6 tablets (0.1 g/tablet) after 6h; Day2~5: 2 tablets (0.1 g/table), BID) - Group 2: Chloroquine Phosphate (Day 1-3: 500 mg BID; Day 4-5: 250 mg BID) Control: none Duration of observation: up to 28 days Primary outcome: Time to Clinical Improvement

Continuación de la tabla.

Active Substance	Hydroxychloroquine Sulfate vs. Chloroquin Phosphate	Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate
Sponsor	Peking University Third Hospital, China	Ruijin Hospital, Shanghai Jiaotong University School of Medicine, China	The First Hospital of Peking University, China
Trial identifier	ChiCTR2000029899	ChiCTR2000029868	ChiCTR2000029740
Study desing	Randomised, parallell assigned, open-label study	Randomised controlled open-label, multicenter trial	Randomised open-label control clinical trial
Status trial	Recruiting	Completed	Recuriting
Duration/End of study	2 months/ Estimated April 30, 2020	6 months/ Estimated end of June 2020	1 month/ Estimated end of February 2020
Study details	Pts: n = 100 Location: China Intervention: - Group 1: Hydroxychloroquine Sulfate (Day1: first dose: 6 tablets (0.1 g/tablet), second dose: 6 tablets (0.1 g/tablet) after 6h; Day2~5: 2 tablets (0.1 g/table), BID) - Group 2: Chloroquine Phosphate (Day 1-3: 500 mg BID; Day 4-5: 250 mg BID) Control: none Duration of observation: up to 28 days Primary outcome: Time to Clinical Improvement	Pts:: n = 360 Group1:n=180 Group2:n=180 Location: China Intervention: Oral Hydroxychloroquine Sulfate tablets (group 1) Control: Conventional treatment (group 2) Duration of observation: Not reported Primary outcome: Viral nucleic acid test	Pts: n = 78 Group 1: n = 54 Group 2: n = 24 Location: China Intervention: Oral Hydroxychloroquine Sulfate tablets (group 1) Control: Conventional therapy (group 2) Duration of observation: 4 weeks Primary outcome: - Oxygen index - Max respiratory rate - Lung radiography - Count of lymphocyte - Temperature - Other infection - Time when the nuleic acid of the novel Covid-19 turns negative